{"id":"daunorubicin-or-idarubicin","safety":{"commonSideEffects":[{"rate":null,"effect":"Cardiotoxicity / cardiomyopathy"},{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Secondary malignancy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These drugs belong to the anthracycline class and work by inserting themselves between DNA base pairs (intercalation) and blocking topoisomerase II, an enzyme essential for DNA replication and transcription. This dual mechanism causes double-strand DNA breaks and apoptosis in rapidly dividing cancer cells. They are particularly effective against hematologic malignancies.","oneSentence":"Daunorubicin and idarubicin are anthracycline chemotherapy agents that intercalate into DNA and inhibit topoisomerase II, leading to DNA damage and cancer cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:52.084Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML)"},{"name":"Acute lymphoblastic leukemia (ALL)"},{"name":"Chronic myeloid leukemia (CML) in blast crisis"}]},"trialDetails":[{"nctId":"NCT04190550","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-04","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","enrollment":24},{"nctId":"NCT05260528","phase":"PHASE2","title":"CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2023-05-03","conditions":"Acute Myeloid Leukemia","enrollment":248},{"nctId":"NCT07407140","phase":"PHASE3","title":"VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-30","conditions":"AML, Adult","enrollment":300},{"nctId":"NCT07486479","phase":"PHASE3","title":"Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-03-10","conditions":"Acute Myeloid Leukemia (AML)","enrollment":204},{"nctId":"NCT06928376","phase":"PHASE2","title":"A Multicenter RCT of \"3+7\" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-04-18","conditions":"Acute Myeloid Leukemia, First Line Therapy","enrollment":160},{"nctId":"NCT03591510","phase":"PHASE2","title":"A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2019-03-13","conditions":"FLT3-mutated Acute Myeloid Leukemia","enrollment":22},{"nctId":"NCT05453903","phase":"PHASE1","title":"A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-10-04","conditions":"Leukemia, Myeloid, Acute","enrollment":196},{"nctId":"NCT06713837","phase":"PHASE3","title":"IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2025-02-27","conditions":"Acute Myeloid Leukemia, Relapse/Recurrence","enrollment":339},{"nctId":"NCT03226418","phase":"PHASE2","title":"Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2017-07-07","conditions":"Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia","enrollment":75},{"nctId":"NCT04375631","phase":"PHASE1","title":"CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-12-03","conditions":"Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome","enrollment":120},{"nctId":"NCT03214562","phase":"PHASE1, PHASE2","title":"Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-09-26","conditions":"High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":116},{"nctId":"NCT07132684","phase":"PHASE3","title":"Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-08-31","conditions":"AML, Adult","enrollment":240},{"nctId":"NCT04263181","phase":"","title":"AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2020-01-29","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":80},{"nctId":"NCT06578247","phase":"PHASE3","title":"Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-11-19","conditions":"Leukemia","enrollment":700},{"nctId":"NCT02339740","phase":"PHASE3","title":"Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2015-07-21","conditions":"Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA","enrollment":158},{"nctId":"NCT06226571","phase":"PHASE1","title":"A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias","status":"RECRUITING","sponsor":"Syndax Pharmaceuticals","startDate":"2024-05-21","conditions":"Acute Myeloid Leukemias","enrollment":76},{"nctId":"NCT03165851","phase":"","title":"Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2005-04-10","conditions":"Acute Myeloid Leukemia, Pediatric","enrollment":320},{"nctId":"NCT07046078","phase":"PHASE2","title":"Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-26","conditions":"Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":20},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":206},{"nctId":"NCT03926624","phase":"PHASE3","title":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","status":"TERMINATED","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2019-11-22","conditions":"Leukemia, Myeloid, Acute","enrollment":167},{"nctId":"NCT07228273","phase":"PHASE2","title":"Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-12-12","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":102},{"nctId":"NCT06068621","phase":"PHASE2","title":"Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2023-03-01","conditions":"Acute Myeloid Leukemia","enrollment":200},{"nctId":"NCT04047641","phase":"PHASE1, PHASE2","title":"Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-22","conditions":"Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome","enrollment":80},{"nctId":"NCT02881086","phase":"PHASE3","title":"Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment","status":"COMPLETED","sponsor":"Goethe University","startDate":"2016-08","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":1023},{"nctId":"NCT05955261","phase":"PHASE2","title":"A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia","status":"SUSPENDED","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-07-25","conditions":"Acute Myeloid Leukemia","enrollment":70},{"nctId":"NCT03117751","phase":"PHASE2, PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma","enrollment":790},{"nctId":"NCT03330821","phase":"PHASE1, PHASE2","title":"Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2018-04-18","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Therapy-Related Acute Myeloid Leukemia","enrollment":53},{"nctId":"NCT02421939","phase":"PHASE3","title":"A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2015-10-20","conditions":"Leukemia, Acute Myeloid (AML)","enrollment":371},{"nctId":"NCT06001788","phase":"PHASE1","title":"Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Kura Oncology, Inc.","startDate":"2024-02-22","conditions":"AML, AML With Mutated NPM1, Hematologic Malignancy","enrollment":171},{"nctId":"NCT00534469","phase":"PHASE2","title":"Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2000-02-08","conditions":"Leukemia","enrollment":60},{"nctId":"NCT06451861","phase":"PHASE2","title":"Randomized Study of ABC-14 Regimen Compared With \"3+7\" Standard Induction Therapy or AB-14 for ND AML","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-08-21","conditions":"Acute Myeloid Leukemia","enrollment":240},{"nctId":"NCT04801797","phase":"PHASE2","title":"Venetoclax + Azacitidine vs. Induction Chemotherapy in AML","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2021-05-20","conditions":"Acute Myeloid Leukemia","enrollment":172},{"nctId":"NCT06928662","phase":"PHASE1, PHASE2","title":"Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-23","conditions":"Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia","enrollment":36},{"nctId":"NCT02115295","phase":"PHASE2","title":"Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-05-19","conditions":"Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","enrollment":508},{"nctId":"NCT07223814","phase":"PHASE3","title":"Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)","status":"NOT_YET_RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2025-12","conditions":"Acute Myeloid Leukemia","enrollment":875},{"nctId":"NCT00801489","phase":"PHASE2","title":"Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-04-04","conditions":"Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1","enrollment":270},{"nctId":"NCT03860844","phase":"PHASE2","title":"Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":67},{"nctId":"NCT02310321","phase":"PHASE1, PHASE2","title":"A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2015-02-26","conditions":"Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia","enrollment":97},{"nctId":"NCT07131059","phase":"NA","title":"MRD-positive AML Clinical Study","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-05-11","conditions":"AML, Adult","enrollment":120},{"nctId":"NCT07108530","phase":"PHASE2","title":"Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-06","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT06930105","phase":"PHASE2","title":"Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL","status":"NOT_YET_RECRUITING","sponsor":"Xianmin Song, MD","startDate":"2025-09-01","conditions":"Acute Lymphoid Leukemia (ALL)","enrollment":45},{"nctId":"NCT06265545","phase":"NA","title":"Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-02-22","conditions":"AML, Refractory, Relapsed","enrollment":120},{"nctId":"NCT07078591","phase":"PHASE2","title":"Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2025-06-20","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT04687176","phase":"PHASE2","title":"Frontline Oral Arsenic Trioxide for APL","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2021-01-01","conditions":"Acute Promyelocytic Leukemia","enrollment":100},{"nctId":"NCT06744556","phase":"PHASE2","title":"HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-01-21","conditions":"AML","enrollment":60},{"nctId":"NCT06066242","phase":"NA","title":"Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-10-01","conditions":"Acute Myeloid Leukemia","enrollment":90},{"nctId":"NCT02632708","phase":"PHASE1","title":"Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2015-12-31","conditions":"Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS)","enrollment":153},{"nctId":"NCT05586074","phase":"PHASE3","title":"HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML","status":"RECRUITING","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2023-03-03","conditions":"Leukemia, Acute Myeloid (AML)","enrollment":324},{"nctId":"NCT01518556","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Konkuk University Medical Center","startDate":"2011-07","conditions":"Leukemia, Myeloid, Acute","enrollment":49},{"nctId":"NCT02834390","phase":"PHASE1","title":"Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2016-08-12","conditions":"Acute Myeloid Leukemia","enrollment":7},{"nctId":"NCT06810791","phase":"PHASE3","title":"HVA vs IA/DA or VA in the Treatment of ND HR-AML","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-01-01","conditions":"Newly Diagnosed Acute Myeloid Leukemia With High Risk","enrollment":876},{"nctId":"NCT04778397","phase":"PHASE3","title":"Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2021-07-01","conditions":"Acute Myeloid Leukemia","enrollment":258},{"nctId":"NCT06529250","phase":"NA","title":"Intermediate-dose HAD Regimen for CEBPA Double-mutated AML","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-08-13","conditions":"AML","enrollment":148},{"nctId":"NCT05177731","phase":"PHASE3","title":"Venetoclax + Decitabine vs. \"7+3\" Induction Chemotherapy in Young AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chen Suning","startDate":"2022-03-01","conditions":"AML, Adult, Chemotherapy Effect","enrollment":188},{"nctId":"NCT02096055","phase":"PHASE2","title":"Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-04-04","conditions":"Untreated Adult Acute Myeloid Leukemia","enrollment":44},{"nctId":"NCT02907359","phase":"PHASE3","title":"Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2017-01-13","conditions":"Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic","enrollment":417},{"nctId":"NCT06221683","phase":"PHASE2","title":"Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML","status":"RECRUITING","sponsor":"Children's Hospital of Soochow University","startDate":"2024-01-01","conditions":"AML, Childhood, Acute Myeloid Leukemia","enrollment":500},{"nctId":"NCT06316960","phase":"PHASE2","title":"Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation","status":"RECRUITING","sponsor":"Children's Hospital of Soochow University","startDate":"2024-03-01","conditions":"AML, Childhood, Relapse/Recurrence, Refractory AML","enrollment":50},{"nctId":"NCT02416388","phase":"PHASE2, PHASE3","title":"Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR","status":"RECRUITING","sponsor":"University Hospital, Angers","startDate":"2015-01","conditions":"Acute Myeloid Leukemia (AML)","enrollment":3100},{"nctId":"NCT02668653","phase":"PHASE3","title":"Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2016-09-01","conditions":"Acute Myeloid Leukemia, Leukemia","enrollment":539},{"nctId":"NCT06497062","phase":"PHASE2","title":"Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-09-04","conditions":"Acute Myeloid Leukemia","enrollment":47},{"nctId":"NCT06492408","phase":"PHASE2","title":"Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2024-07-01","conditions":"Hepatic Cancer, Surgery","enrollment":90},{"nctId":"NCT06492421","phase":"PHASE2","title":"Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2024-07-01","conditions":"Lung Cancer, Surgery, Non-small Cell Lung Cancer","enrollment":90},{"nctId":"NCT06483347","phase":"PHASE2","title":"Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2024-04-04","conditions":"Lung Cancer, Inoperable Disease","enrollment":90},{"nctId":"NCT06482801","phase":"PHASE2","title":"Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2024-06-10","conditions":"Liver Cancer, Antibody","enrollment":90},{"nctId":"NCT05304156","phase":"","title":"Single-cell Dynamic Profiling in Adults With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy. A THEMA Study\"","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-04-26","conditions":"Acute Myeloid Leukemia","enrollment":200},{"nctId":"NCT04571645","phase":"PHASE3","title":"Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2021-04-30","conditions":"Acute Myeloid Leukemia","enrollment":9},{"nctId":"NCT02135874","phase":"PHASE2","title":"Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-10-27","conditions":"Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage","enrollment":16},{"nctId":"NCT03379727","phase":"PHASE3","title":"Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-02-13","conditions":"Acute Myeloid Leukemia","enrollment":301},{"nctId":"NCT02013648","phase":"PHASE3","title":"Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)","status":"COMPLETED","sponsor":"University of Ulm","startDate":"2014-07","conditions":"Acute Myeloid Leukemia (AML)","enrollment":204},{"nctId":"NCT02441803","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-14","conditions":"Leukemia","enrollment":11},{"nctId":"NCT06232694","phase":"NA","title":"Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-01-01","conditions":"Acute Myeloid Leukemia","enrollment":54},{"nctId":"NCT05020665","phase":"PHASE3","title":"Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML","status":"TERMINATED","sponsor":"Kronos Bio","startDate":"2021-11-24","conditions":"Nucleophosmin 1-mutated Acute Myeloid Leukemia","enrollment":15},{"nctId":"NCT02873338","phase":"PHASE2","title":"Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2016-08","conditions":"Acute Myeloid Leukemia","enrollment":75},{"nctId":"NCT03512197","phase":"PHASE3","title":"A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-07-20","conditions":"Acute Myeloid Leukemia (AML)","enrollment":511},{"nctId":"NCT05313958","phase":"PHASE2, PHASE3","title":"Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-12-01","conditions":"Leukemia, Monocytic, Acute, Pediatric AML","enrollment":43},{"nctId":"NCT02665065","phase":"PHASE3","title":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actinium Pharmaceuticals","startDate":"2016-06","conditions":"Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute","enrollment":153},{"nctId":"NCT04687098","phase":"PHASE2","title":"Risk-adapted Therapy for Primary Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias","startDate":"2012-02-01","conditions":"Leukemia, Myeloid, Acute","enrollment":1034},{"nctId":"NCT00002868","phase":"PHASE3","title":"Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1997-11-20","conditions":"Leukemia","enrollment":744},{"nctId":"NCT02172872","phase":"PHASE3","title":"\"InDACtion\" vs \"3+7\" Induction in AML","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2014-11-28","conditions":"Acute Myeloid Leukemia (AML)","enrollment":606},{"nctId":"NCT03194932","phase":"PHASE1","title":"Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-07-11","conditions":"Acute Myeloid Leukemia","enrollment":62},{"nctId":"NCT02703272","phase":"PHASE3","title":"A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-07-01","conditions":"Lymphoma, Non-Hodgkin","enrollment":72},{"nctId":"NCT00866918","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2009-03-09","conditions":"Childhood Acute Promyelocytic Leukemia With PML-RARA, Myeloid Neoplasm","enrollment":106},{"nctId":"NCT00482833","phase":"PHASE3","title":"Phase III Trial in Acute Promyelocytic Leukemia Patients","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2007-08","conditions":"Leukemia","enrollment":276},{"nctId":"NCT04248595","phase":"PHASE2","title":"Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML","status":"UNKNOWN","sponsor":"Ge Zheng","startDate":"2019-12-01","conditions":"Acute Myeloid Leukemia","enrollment":100},{"nctId":"NCT03173612","phase":"NA","title":"The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-08","conditions":"Acute Myeloid Leukemia","enrollment":132},{"nctId":"NCT04676243","phase":"PHASE3","title":"Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML","status":"WITHDRAWN","sponsor":"University Hospital Heidelberg","startDate":"2022-05","conditions":"Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT05053425","phase":"NA","title":"Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML","status":"UNKNOWN","sponsor":"LanZhou University","startDate":"2021-10-20","conditions":"Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT04112589","phase":"PHASE1, PHASE2","title":"A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment","status":"UNKNOWN","sponsor":"PETHEMA Foundation","startDate":"2019-12-26","conditions":"Acute Myeloid Leukemia","enrollment":63},{"nctId":"NCT02464657","phase":"PHASE1, PHASE2","title":"Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-07","conditions":"Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":44},{"nctId":"NCT03257241","phase":"PHASE3","title":"A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old","status":"UNKNOWN","sponsor":"Polish Adult Leukemia Group","startDate":"2017-07-03","conditions":"Acute Myeloid Leukemia","enrollment":582},{"nctId":"NCT05053386","phase":"NA","title":"Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2021-10","conditions":"Hepatocellular Carcinoma","enrollment":186},{"nctId":"NCT02249091","phase":"PHASE2","title":"A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"GSO Global Clinical Research BV","startDate":"2014-09","conditions":"Acute Myeloid Leukemia (Relapsed/Refractory)","enrollment":42},{"nctId":"NCT02440568","phase":"PHASE1, PHASE2","title":"AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients","status":"TERMINATED","sponsor":"University of Illinois at Chicago","startDate":"2015-06-05","conditions":"Acute Myeloid Leukemia","enrollment":22},{"nctId":"NCT01296178","phase":"NA","title":"PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years","status":"UNKNOWN","sponsor":"PETHEMA Foundation","startDate":"2010-12","conditions":"Acute Myeloblastic Leukemia","enrollment":200},{"nctId":"NCT01180322","phase":"PHASE2","title":"Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine","status":"COMPLETED","sponsor":"University of Ulm","startDate":"2010-11","conditions":"Acute Myeloid Leukemia (AML)","enrollment":277},{"nctId":"NCT00831766","phase":"PHASE1, PHASE2","title":"Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2009-06-25","conditions":"Myelodysplastic Syndrome, Acute Myeloid Leukemia","enrollment":51},{"nctId":"NCT00067028","phase":"PHASE2","title":"Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2003-12","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia","enrollment":116},{"nctId":"NCT02046122","phase":"PHASE1, PHASE2","title":"Adoptive Transfer of Haplo-identical DLI for AML and MDS","status":"COMPLETED","sponsor":"Duke University","startDate":"2014-07","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":19},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":81176,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Part 1 Block 2 induction FLADx"],"phase":"phase_3","status":"active","brandName":"Daunorubicin or Idarubicin","genericName":"Daunorubicin or Idarubicin","companyName":"Stichting Hemato-Oncologie voor Volwassenen Nederland","companyId":"stichting-hemato-oncologie-voor-volwassenen-nederland","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Daunorubicin and idarubicin are anthracycline chemotherapy agents that intercalate into DNA and inhibit topoisomerase II, leading to DNA damage and cancer cell death. Used for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Chronic myeloid leukemia (CML) in blast crisis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}